DS

Darko Skegro

GS Glenmark Pharmaceuticals S.A.: 5 patents #19 of 189Top 15%
IS Ichnos Sciences Sa.: 4 patents #5 of 28Top 20%
SA Sanofi: 2 patents #699 of 1,881Top 40%
NA Novartis Ag: 1 patents #2,882 of 5,128Top 60%
Overall (All Time): #401,353 of 4,157,543Top 10%
12
Patents All Time

Issued Patents All Time

Showing 1–12 of 12 patents

Patent #TitleCo-InventorsDate
12006367 CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production Romain Ollier, Samuel Hou, Rami Lissilaa, Jonathan Back 2024-06-11
11891454 Production of T cell retargeting hetero-dimeric immunoglobulins Stanislas Blein, Romain Ollier, Samuel Hou 2024-02-06
11851502 Production of T cell retargeting hetero-dimeric immunoglobulins Stanislas Blein, Romain Ollier, Samuel Hou 2023-12-26
11773166 CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production Romain Ollier, Samuel Hou, Rami Lissilaa, Jonathan Back 2023-10-03
11685776 Engineered heterodimeric proteins Regis Cebe, Sebastien IRIGARAY 2023-06-27
11267891 Fc variant antibodies and their uses Stanislas Blein, Samuel Hou 2022-03-08
9683052 Hetero-dimeric immunoglobulins Stanislas Blein, Paul Wassmann 2017-06-20
9683053 Hetero-dimeric immunoglobulins Stanislas Blein, Paul Wassmann 2017-06-20
9493563 Production of T cell retargeting hetero-dimeric immunoglobulins Stanislas Blein, Romain Ollier, Samuel Hou 2016-11-15
9290576 Antibodies that bind to TL1A and their uses Antoine Attinger, Jonathan Back, Stanislas Blein, Rami Lissilaa 2016-03-22
8975376 Anti-alpha2 integrin antibodies and their uses Stanislas Blein, Samuel Hou 2015-03-10
8679492 Humanized antibodies that bind to CD19 and their uses Stanislas Blein, Christophe Debonneville, Martin Bertschinger 2014-03-25